Memantine
- Generic Name
- Memantine
- Brand Names
- Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21N
- CAS Number
- 19982-08-2
- Unique Ingredient Identifier
- W8O17SJF3T
- Background
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...
- Indication
Memantine is used to manage moderate to severe Alzheimer's dementia .
...
- Associated Conditions
- Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
Memantine and Post-mastectomy Neuropathic Pain
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Target Recruit Count
- 150
- Registration Number
- NCT03686774
- Locations
- 🇫🇷
Chu Clermont-Ferrand, Clermont-Ferrand, France
Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 64
- Registration Number
- NCT03670095
- Locations
- 🇨🇳
Shuguang Hospital, Shanghai TCM University, Shanghai, China
Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
- Conditions
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03553875
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 206
- Registration Number
- NCT03550391
- Locations
- 🇺🇸
University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸City of Hope Corona, Corona, California, United States
Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT03527472
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸The University of Texas Health Science Center, Houston, Houston, Texas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Effect of Memantine on Radiotherapy-related Cognitive Impairment
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-04-12
- Target Recruit Count
- 240
- Registration Number
- NCT03342443
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Allergan
- Registration Number
- NCT03316898
- Locations
- 🇺🇸
Synergy Research Centers, Lemon Grove, California, United States
🇺🇸Collaborative Neuroscience, Long Beach, California, United States
🇺🇸Alliance Research, Long Beach, California, United States
A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 40
- Registration Number
- NCT03247218
- Locations
- 🇮🇱
Emek Medical Centre, Afula, Israel
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT03194906
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Memantine Treatment in Alzheimer's Disease Patients
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Wei Cuibai
- Target Recruit Count
- 222
- Registration Number
- NCT03168997
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.